• Comprehensive Cancer Centre Ulm (CCCU)
• Oncology Centre

see under https://www.uniklinik-ulm.de/comprehensive-cancer-center-ulm-cccu/kooperationspartner-in-der-region.html

The well-being of our patients is at the centre of everything we do. Our aim is to offer our patients the best possible individual treatment, a so-called personalised therapy, at every stage of the disease.

The clinic has 112 inpatient beds, a large, highly specialised university outpatient clinic and a medical oncology day clinic with 25 treatment places. Ward 4CD (the so-called lock wing) with a total of 37 beds is equipped with special air filtration for infection prophylaxis; these wards primarily treat patients with acute leukaemia and patients following high-dose chemotherapy, including autologous blood stem cell transplants.

In regular interdisciplinary case discussions, so-called tumour boards, the latest treatment options are discussed for each individual patient.

We treat patients with the following diseases:

Blood count changes (e.g. anaemia), lymph node enlargement, aplastic anaemia, myeloproliferative diseases (CML, PV, ET, MF), myelodysplasia syndromes (MDS), acute leukaemias (AML, ALL), chronic lymphocytic leukaemia (CLL), Hodgkin's/non-Hodgkin's lymphomas, multiple myeloma, coagulation diseases (thrombophilia, haemophilia); non-malignant haematological diseases.

The unit for allogeneic blood stem cell and bone marrow transplantation (cEBKT) (Head: Dr Elisa Sala) has been in existence since 1978 and is one of the oldest in the world. The unit offers all currently possible variants of allogeneic stem cell transplantation (family donors, unrelated donors, haploidentical donors, umbilical cord blood). Approximately 170-180 allogeneic and autologous stem cell transplants are carried out each year.

All CAR-T cell therapies are also carried out on the ward. CAR-T cell therapy is a new, cellular immunotherapeutic procedure that will only be carried out at highly specialised centres in Germany. The term 'CAR-T' stands for T cells modified with a "chimeric antigen receptor". These are genetically modified T cells of the patient that are able to recognise tumour antigens (e.g. the CD19 antigen in lymphomas and acute lymphatic leukaemias) and attack the tumour cells. We offer this new cellular immunotherapy for a variety of haematological neoplasms (including malignant lymphomas, multiple myeloma, acute leukaemias).

The unit is JACIE (Joint Accreditation Committee-ISCT [Europe] & EBMT) certified for autologous and allogeneic transplants, as a centre for the collection of peripheral blood stem cells and for bone marrow aspirations as well as for CAR-T cell therapies.

It is very important to us to give our patients the opportunity to take part in clinical trials with innovative medicines.

Around 80 clinical trials are coordinated in our study centre (Head: PD Dr Frank Stegelmann). These are studies in phases 1-2 (early development of new, promising, usually not yet approved drugs) or phases 3-4 (so-called therapy optimisation or quality assurance studies).

The Early Clinical Trials Unit (ECTU) carries out early phase studies (phase 1/2) with innovative drugs. The unit is located in the immediate vicinity of the Medical Oncology Day Clinic (MOT). The unit is staffed by study physicians and highly qualified personnel (study nurses, medical assistants, documentalists) who are specially trained in the supervision of clinical trials.

The large number of trials is an enormous innovation factor and gives our patients the opportunity to participate in medical progress at an early stage.

Rapid diagnostic clarification to the highest quality standards at the time of diagnosis, during the course of treatment and in the event of a relapse, carried out by our accredited haematology, molecular and cytogenetic diagnostics laboratories, is the cornerstone for rapid treatment recommendations and initiation. We have access to the latest technologies for genetic characterisation and thus for optimising therapy for our patients.

The accredited Laboratory for Cytogenetic and Molecular Diagnostics (Head: Prof Dr Konstanze Döhner) enjoys a high national and international reputation and is the reference laboratory for genetic diagnostics in numerous study groups, including for the German-Austrian AML Study Group (AMLSG), the German Myeloproliferative Neoplasia Study Group (GSG-MPN), the German CLL Study Group (DCLLSG) (Head: Prof Stephan Stilgenbauer) and the German Multiple Myeloma Study Group (DSMM) (Head: Dr Miriam Kull).

The aim of palliative medicine is to provide holistic care for seriously ill patients in their final stage of life. It aims to maintain and improve the patient's remaining quality of life and enable them to die with dignity. In order to achieve these goals, medical and nursing staff work together with a variety of other professional groups, such as psychosocial and pastoral services, physiotherapists, psycho-oncologists, nutritionists, as well as music and art therapists.

The palliative care ward currently has 8 beds. The ward cooperates with the Agathe Streicher Hospice and the Specialised Outpatient Palliative Care (SAPV) (Ambulante Palliativversorgung Ulm - APU e.V.) as part of the Ulm Palliative Care Network (PNU).

Another important cornerstone in the holistic care of our patients is the network of specialists from various medical, psycho-oncological and nursing disciplines.

Co-operation with established self-help groups enables those affected to strengthen their resources and find ways of coping better with their illness.

ULLM with the Department of Internal Medicine III aims to provide the highest quality of medical care and a patient-friendly service. In addition, the centre's scientific staff strive to conduct basic, translational and clinical research at the highest level.

In order to maintain and further expand our leading position in patient care and research on a national and international level, we rely on private donations in addition to income from patient care, the research and teaching budget and third-party funding from public organisations and non-public foundations.

We would like to thank all patients, relatives and other patrons for their generous support in recent years.

Every donation helps us to successfully advance these ambitious projects.

We have set up donation accounts for the key areas of "Leukaemia and cancer research", "Blood stem cell and bone marrow transplantation", "Palliative medicine" and "VIV-ARTE training concept".

Please always quote the relevant project number; we need your name and address for donation receipts.